investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 22, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14 th Annual Biotech Conference , Wednesday, September 4 , at 8:00 a.m.Read more
– Received EU conditional marketing authorization for ZYNTEGLO ® (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion dependent β-thalassemia (TDT) who do not have a β 0 /β 0 genotype – – Presented data across LentiGlobin® for TDT andRead more
Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT who do not have a β 0 /βRead more